Geneoscopy in May received U.S. Food and Drug Administration Approval for ColoSense, its at-home stool-based screening test for colon cancer. It plans to commercially launch ColoSense later this year or in early 2025. Geneoscopy has raised more than $100 million in financing as it’s sought to bring its colorectal cancer screening test to market. Geneoscopy has 55 employees, with more than half of its workers based in St. Louis…
